BRPI0906877A2 - Anticorpos anti-trkb aperfeiçoados - Google Patents
Anticorpos anti-trkb aperfeiçoadosInfo
- Publication number
- BRPI0906877A2 BRPI0906877A2 BRPI0906877-5A BRPI0906877A BRPI0906877A2 BR PI0906877 A2 BRPI0906877 A2 BR PI0906877A2 BR PI0906877 A BRPI0906877 A BR PI0906877A BR PI0906877 A2 BRPI0906877 A2 BR PI0906877A2
- Authority
- BR
- Brazil
- Prior art keywords
- improved anti
- trkb antibodies
- trkb
- antibodies
- improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2182008P | 2008-01-17 | 2008-01-17 | |
| PCT/US2009/031345 WO2009092049A1 (en) | 2008-01-17 | 2009-01-16 | Improved anti-trkb antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0906877A2 true BRPI0906877A2 (pt) | 2015-07-28 |
Family
ID=40627621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906877-5A BRPI0906877A2 (pt) | 2008-01-17 | 2009-01-16 | Anticorpos anti-trkb aperfeiçoados |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8642035B2 (pt) |
| EP (1) | EP2235062A1 (pt) |
| JP (1) | JP5420568B2 (pt) |
| KR (1) | KR101290503B1 (pt) |
| CN (1) | CN102015769B (pt) |
| AR (1) | AR070202A1 (pt) |
| AU (1) | AU2009205937B2 (pt) |
| BR (1) | BRPI0906877A2 (pt) |
| CA (1) | CA2712298C (pt) |
| CL (1) | CL2009000090A1 (pt) |
| EA (1) | EA028621B1 (pt) |
| MX (1) | MX2010007841A (pt) |
| PE (1) | PE20091326A1 (pt) |
| TW (1) | TW200936608A (pt) |
| WO (1) | WO2009092049A1 (pt) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011036297A2 (de) * | 2009-09-27 | 2011-03-31 | Ruhr-Universität-Bochum | Verfahren zur therapie und diagnose von morbus alzheimer |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| EP3798236B1 (en) | 2011-03-15 | 2022-08-10 | X-Body, Inc. | Antibody screening methods |
| CN102830228B (zh) * | 2011-06-15 | 2015-01-21 | 格诺思博生物科技(上海)有限公司 | 定量分析循环肿瘤细胞的试剂及试剂盒 |
| CN102944674B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法 |
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| EP3013371A4 (en) * | 2013-06-26 | 2017-04-26 | Rett Syndrome Research Trust | Rett syndrome and treatments therefore |
| TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| CN104524568B (zh) * | 2015-01-08 | 2018-04-20 | 中国人民解放军第二军医大学 | 一种治疗肥胖症的药物组合物及其应用 |
| US9869295B2 (en) | 2015-05-07 | 2018-01-16 | General Electric Company | Attachment method to install components, such as tip extensions and winglets, to a wind turbine blade, as well as the wind turbine blade and component |
| US9869296B2 (en) | 2015-05-07 | 2018-01-16 | General Electric Company | Attachment method and system to install components, such as tip extensions and winglets, to a wind turbine blade |
| US9869297B2 (en) | 2015-05-07 | 2018-01-16 | General Electric Company | Attachment method and system to install components, such as vortex generators, to a wind turbine blade |
| HK1253093A1 (zh) | 2015-06-01 | 2019-06-06 | Loxo Oncology Inc. | 诊断和治疗癌症的方法 |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| US10100805B2 (en) | 2015-10-12 | 2018-10-16 | General Electric Compant | Tip extension assembly for a wind turbine rotor blade |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TW201730206A (zh) | 2015-11-17 | 2017-09-01 | 葛蘭素史克智慧財產發展有限公司 | 用於治療神經及其他疾病之結合激動劑 |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| UA125025C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | Способи лікування дитячих ракових захворювань |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018069927A1 (en) * | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| US11286295B2 (en) * | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
| US10443579B2 (en) | 2016-11-15 | 2019-10-15 | General Electric Company | Tip extensions for wind turbine rotor blades and methods of installing same |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11098691B2 (en) | 2017-02-03 | 2021-08-24 | General Electric Company | Methods for manufacturing wind turbine rotor blades and components thereof |
| US10830206B2 (en) | 2017-02-03 | 2020-11-10 | General Electric Company | Methods for manufacturing wind turbine rotor blades and components thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3635122A4 (en) | 2017-06-06 | 2021-03-31 | University of Massachusetts | SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME |
| US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| US10865769B2 (en) | 2017-11-21 | 2020-12-15 | General Electric Company | Methods for manufacturing wind turbine rotor blade panels having printed grid structures |
| US10920745B2 (en) | 2017-11-21 | 2021-02-16 | General Electric Company | Wind turbine rotor blade components and methods of manufacturing the same |
| US11390013B2 (en) | 2017-11-21 | 2022-07-19 | General Electric Company | Vacuum forming mold assembly and associated methods |
| US10773464B2 (en) | 2017-11-21 | 2020-09-15 | General Electric Company | Method for manufacturing composite airfoils |
| US11668275B2 (en) | 2017-11-21 | 2023-06-06 | General Electric Company | Methods for manufacturing an outer skin of a rotor blade |
| US11040503B2 (en) | 2017-11-21 | 2021-06-22 | General Electric Company | Apparatus for manufacturing composite airfoils |
| US11248582B2 (en) | 2017-11-21 | 2022-02-15 | General Electric Company | Multiple material combinations for printed reinforcement structures of rotor blades |
| US10821652B2 (en) | 2017-11-21 | 2020-11-03 | General Electric Company | Vacuum forming mold assembly and method for creating a vacuum forming mold assembly |
| US10913216B2 (en) | 2017-11-21 | 2021-02-09 | General Electric Company | Methods for manufacturing wind turbine rotor blade panels having printed grid structures |
| KR102986081B1 (ko) | 2017-11-30 | 2026-07-06 | 리제너론 파아마슈티컬스, 인크. | 항-trkb 모노클로날 항체 및 이의 사용 방법 |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN108265036B (zh) * | 2018-01-26 | 2021-04-27 | 山东大学齐鲁医院 | 一种沉默t1蛋白的重组病毒及其构建方法与应用 |
| US11035339B2 (en) | 2018-03-26 | 2021-06-15 | General Electric Company | Shear web assembly interconnected with additive manufactured components |
| US10821696B2 (en) | 2018-03-26 | 2020-11-03 | General Electric Company | Methods for manufacturing flatback airfoils for wind turbine rotor blades |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| CA3108065C (en) | 2018-07-31 | 2025-10-07 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| AU2023246202A1 (en) | 2022-03-30 | 2024-10-17 | Peptidream Inc | Peptide complex having trkb binding activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22979A1 (es) | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| KR20090088896A (ko) * | 2006-11-09 | 2009-08-20 | 아이알엠 엘엘씨 | 효현제 ｔｒｋｂ 항체 및 그의 용도 |
| KR20100089851A (ko) * | 2007-10-23 | 2010-08-12 | 노파르티스 아게 | 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도 |
-
2009
- 2009-01-16 JP JP2010543295A patent/JP5420568B2/ja not_active Expired - Fee Related
- 2009-01-16 TW TW098101724A patent/TW200936608A/zh unknown
- 2009-01-16 AU AU2009205937A patent/AU2009205937B2/en not_active Ceased
- 2009-01-16 BR BRPI0906877-5A patent/BRPI0906877A2/pt not_active Application Discontinuation
- 2009-01-16 CN CN200980109719.6A patent/CN102015769B/zh not_active Expired - Fee Related
- 2009-01-16 CL CL2009000090A patent/CL2009000090A1/es unknown
- 2009-01-16 MX MX2010007841A patent/MX2010007841A/es active IP Right Grant
- 2009-01-16 EP EP09702204A patent/EP2235062A1/en not_active Ceased
- 2009-01-16 PE PE2009000058A patent/PE20091326A1/es not_active Application Discontinuation
- 2009-01-16 WO PCT/US2009/031345 patent/WO2009092049A1/en not_active Ceased
- 2009-01-16 US US12/864,636 patent/US8642035B2/en active Active
- 2009-01-16 KR KR1020107018153A patent/KR101290503B1/ko not_active Expired - Fee Related
- 2009-01-16 CA CA2712298A patent/CA2712298C/en not_active Expired - Fee Related
- 2009-01-16 EA EA201001139A patent/EA028621B1/ru not_active IP Right Cessation
- 2009-01-19 AR ARP090100159A patent/AR070202A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101290503B1 (ko) | 2013-07-26 |
| US20110097326A1 (en) | 2011-04-28 |
| MX2010007841A (es) | 2010-09-28 |
| KR20100103693A (ko) | 2010-09-27 |
| CL2009000090A1 (es) | 2009-07-24 |
| WO2009092049A1 (en) | 2009-07-23 |
| CN102015769A (zh) | 2011-04-13 |
| EA028621B1 (ru) | 2017-12-29 |
| CA2712298A1 (en) | 2009-07-23 |
| PE20091326A1 (es) | 2009-09-18 |
| EP2235062A1 (en) | 2010-10-06 |
| AU2009205937B2 (en) | 2013-02-07 |
| AR070202A1 (es) | 2010-03-17 |
| CA2712298C (en) | 2015-11-24 |
| AU2009205937A1 (en) | 2009-07-23 |
| CN102015769B (zh) | 2014-12-10 |
| US8642035B2 (en) | 2014-02-04 |
| TW200936608A (en) | 2009-09-01 |
| EA201001139A1 (ru) | 2011-04-29 |
| JP5420568B2 (ja) | 2014-02-19 |
| JP2011510021A (ja) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019004I1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| IL212175B (en) | Muc1* antibodies | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| HUE056626T2 (hu) | Antitestkészítmény | |
| PT2406284T (pt) | Anticorpos anti-bcma | |
| BRPI0917148A2 (pt) | anticorpos anti-cd5 | |
| BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
| BRPI0912173A2 (pt) | anticorpos anti-flt3 | |
| BRPI0922800A2 (pt) | anticorpos c-met | |
| BRPI0923359A2 (pt) | Anticorpos anti-igf | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| HRP20150224T1 (xx) | Anti-mif protutijela | |
| EP2262831A4 (en) | ANTI-properdin antibody | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| EP2207803A4 (en) | CD9-SPECIFIC HUMAN ANTIBODIES | |
| DE602008003521D1 (de) | Sitzrücklehnungsmechanismus | |
| BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
| DE602008003970D1 (de) | Strahlstromkalibriersystem | |
| EP2318641A4 (en) | BOHRROHRZENTRIERER | |
| BRPI0907522A2 (pt) | biarlamidas | |
| BRPI0915562A2 (pt) | tamis melhorado | |
| BRPI0915442A2 (pt) | tamis melhorado | |
| DE112009000183A5 (de) | Sicherheitsvorreiber |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) |
|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |